Compare ADMA Biologics Inc (ADMA) vs Autozone Inc (AZO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Autozone Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Autozone Inc trades at $3,072.08 (market cap $50.20B). The key difference: Autozone Inc is far larger — about 23.6× ADMA Biologics Inc's market cap, and Autozone Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AZO | |
|---|---|---|
Market Cap | $2.13B | $50.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $4.35K |
52-Week Low | $7.60 | $2.94K |
Enterprise Value | $2.20B | $62.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AutoZone (AZO) trades at $3,074.86, down 2.67% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though profit margins have declined from 14.94% in 2022 to 13.19% in 2025. Recent Q1 2026 earnings beat expectations at $38.07 EPS versus $36.22 expected, while the board authorized an additional $1.5B stock repurchase in June 2026.
AZO presents a mixed outlook with 72.7% analyst buy ratings and $3,740 consensus target suggesting 21.6% upside, but faces technical headwinds and margin compression risks. Investment appeal hinges on international expansion execution and commercial segment growth offsetting domestic softness noted in recent earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
